| Autor: |
Radocha J; 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz.; Czech Myeloma Group, Brno, Czech Republic. jakub.radocha@centrum.cz., Hájek R; Czech Myeloma Group, Brno, Czech Republic.; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic., Brožová L; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Pour L; Czech Myeloma Group, Brno, Czech Republic.; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine Masaryk Universtiy, University Hospital Brno, Brno, Czech Republic., Špička I; Czech Myeloma Group, Brno, Czech Republic.; 1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic., Minařík J; Czech Myeloma Group, Brno, Czech Republic.; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic., Gregora E; Czech Myeloma Group, Brno, Czech Republic.; Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic., Jungová A; Czech Myeloma Group, Brno, Czech Republic.; Hematology and Oncology Department, Charles University Hospital Pilsen, Prague, Czech Republic., Jelínek T; Czech Myeloma Group, Brno, Czech Republic.; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic., Heindorfer A; Czech Myeloma Group, Brno, Czech Republic.; Department of Clinical Hematology, Hospital Liberec, Liberec, Czech Republic., Sýkora M; Czech Myeloma Group, Brno, Czech Republic.; Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic., Maisnar V; 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic.; Czech Myeloma Group, Brno, Czech Republic. |
| Abstrakt: |
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years. |
Full text from SpringerLink